SCHEMBL6496767

SCHEMBL6496767

Cc1ccccc1-c1ccc(C(=O)NC2CC3CNC2C3)o1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HPGD P15428 5/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPT P10636 4/20 0.45
LMNA P02545 3/20 0.45
MAPK1 P28482 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
RECQL P46063 1/20 0.45
KMT2A Q03164 1/20 0.45
SLC9A1 P19634 1/20 0.43
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
S1PR4 O95977 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487086 0.88 ALDH1A1 (0.51) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6486252 0.88 RAB9A (0.41) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6495236 0.87 RAB9A (0.49) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6488527 0.87 RAB9A (0.55) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6489007 0.87 SLC9A1 (0.44) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6488989 0.85 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6488167 0.84 S1PR4 (0.43) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6501627 0.82 MMP13 (0.43) ALDH1A1HPGDKDM4EMAPTLMNA
SCHEMBL6500540 0.82 HDAC1 (0.48) ALDH1A1HPGDKDM4E
SCHEMBL6489150 0.82 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
EP-1442041-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-08-04 EP disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
WO-2003040147-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ PHARMACIA & UPJOHN COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885HPGD 706/4885KDM4E 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.